Sartorius stock trades at EUR 250.35 with a P/ E of 88.4

Published on 10/09/2026 at 15:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays lifted its target to EUR 310 on September 30, 2026. Sartorius stock costs EUR 250.35 on October 9, 2026 after EUR 248.65, plus 0.68 percent.

Sartorius stock was trading at EUR 250.35 at Lang & Schwarz on October 9, 2026, plus 0.68 percent versus the prior close.
The price was 7.9 percent below the 52-week high of EUR 271.90 and the market capitalization was EUR 17.3 billion.
The P/E ratio was 88.4, while Danaher and Thermo Fisher traded at P/E ratios of 38.6 and 35.1, respectively.
Sartorius is scheduled to report nine-month 2026 results on October 22, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius (ISIN DE0007165631) was trading at EUR 250.35 at Lang & Schwarz on October 9, 2026 at 3:12 p.m. CEST, plus 0.68 percent versus the prior close of EUR 248.65. The price report places the shares below their yearly peak while the next results date approaches.

Price stays below yearly high

The Lang & Schwarz price stood 7.9 percent below Sartorius' 52-week high of EUR 271.90 and 26.1 percent above the 52-week low of EUR 198.50, based on the same-day market snapshot from October 9, 2026. The market capitalization was EUR 17.3 billion, and the P/E ratio was 88.4.

Trading activity was 10,939 shares against an average volume of 98,975 shares in the latest primary-market quote. The Xetra listing carried the SRT3 ticker, and the stock was included in the MDAX.

Valuation remains the key comparison

According to FinanzNachrichten on September 30, 2026, Barclays raised its target from EUR 300 to EUR 310 and retained an Overweight rating. The EUR 310 target lies 23.8 percent above the Lang & Schwarz price.

The valuation gap is visible against two large life-science peers. The comparison uses October 8, 2026 home-market snapshots.

Comparison with peers

Sartorius: plus 0.68 percent, P/E 88.4, market capitalization EUR 17.3 billion

Danaher (NYSE, USD): minus 0.47 percent, P/E 38.6, market capitalization USD 152.9 billion

Thermo Fisher Scientific (NYSE, USD): minus 1.52 percent, P/E 35.1, market capitalization USD 241.1 billion

Results date is October 22

Sartorius lists its nine-month 2026 results conference for October 22, 2026 at 1:00 p.m. CEST. That date gives the market a defined checkpoint for the fiscal 2026 outlook, which calls for sales revenue growth of 5 to 9 percent in constant currencies and an underlying EBITDA margin above 30 percent.

Price and market snapshot

Sartorius was trading at EUR 250.35 at Lang & Schwarz on October 9, 2026 at 3:12 p.m. CEST, up 0.68 percent on the session and 7.9 percent below the 52-week high of EUR 271.90. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.